home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

PI 3-Kinase Signaling Pathways in Disease

  June 15, 2006  

Keystone Symposia, Santa Fe, New Mexico
February 15 - 20, 2007

The PI 3-kinase signaling pathway is emerging as a promising therapeutic target in a number of human diseases including cancer, inflammation and heart disease. Mutations in the PIK3CA gene and the deletion of lipid phosphatase, PTEN, are widespread in many tumors. Mouse models which target individual PI 3-kinase isoforms have shed light on the roles of these enzymes in immune cell function, mast cell degranulation and leukocyte migration. One of the most exciting developments in this field is the discovery of new PI 3-kinase inhibitors. However, identifying the indications that will provide the best opportunity to develop these inhibitors is the subject of intense debate. This meeting aims to bring together scientists and clinicians from academia and industry to discuss the opportunities and liabilities of targeting the PI 3-kinase pathway in disease, drawing on human pathophysiology and genetics, mouse models and preclinical data with new PI 3-kinase inhibitors.
Organized by: Peter M. Finan and Lewis C. Cantley
Invited Speakers: - Dario Alessi, University of Dundee
- Morris Birnbaum, University of Pennsylvania School of Medicine
- Lewis Cantley, Harvard Medical School
- Jan Domin, Imperial College London
- David Fruman, University of California, Irvine
- Carlos Garcia-Echeverria, Novartis Pharma AG
- Joel Hayflick, ICOS Corporation
- Brian Hemmings, Friedrich Miescher Institute for Biomedical Research
- Emilio Hirsch, University of Torino
- Takashi Kadowaki, University of Tokyo
- Heidi Lane, Novartis Pharma AG
- Yan Luo, Abbott Laboratories
- Brendan Manning, Harvard School of Public Health
- Pier Paolo Pandolfi, Memorial Sloan-Kettering Cancer Center
- Thomas Roberts, Dana Farber Cancer Institute
- Christian Rommel, Serono International S.A.
- David Sabatini, Whitehead Institute for Biomedical Research
- Charles Sawyers, Memorial Sloan Kattering
- William Sellers, Novartis Institutes for BioMedical Research
- Kevan Shokat, University of California, San Francisco
- Len Stephens, Babraham Institute
- George Thomas, University of Cincinnati
- Bart Vanhaesebroeck, Ludwig Institute for Cancer Research
- Paul Workman, Institute of Cancer Research
- Matthias Wymann, University of Basel
Deadline for Abstracts: Oct. 16, 2006
Registration: Please see website
E-mail: info@keystonesymposia.org
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.